This website uses cookies, pixels, and similar technologies (“cookies”), some of which are provided by third parties, to enable website features and functionality; measure, analyze, and improve site performance; enhance user experience; record user interactions; and support our advertising and marketing. We and our third-party vendors may monitor, record, and access information and data, including device data, IP address and online identifiers, referring URLs and other browsing information, for these and similar purposes. By clicking “Accept all cookies,” you agree to such purposes. If you continue to browse our site without clicking “Accept all cookies,” or if you click “Reject all cookies,” only cookies necessary to operate and enable default website features and functionalities will be deployed. If you are visiting our Site in the U.S., by using this site or clicking “Accept all cookies,” “Reject all cookies,” or “Preferences,” you acknowledge and agree to our Privacy Policy, Cookie Policy, and Terms of Use.
Accept all cookiesReject all cookiesPreferences
mission
portfolioknowledge hub
about
careers

library

IQT News
/
No items found.

Kailos Genetics Announces Strategic Investment and Partnership with In-Q-Tel

July 11, 2017
Read the Paper

Partnership will further develop Kailos' leading-edge next-generation sequencing solutions for the intelligence community‍

July 11, 2017

‍Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced a strategic partnership with and investment from In-Q-Tel, Inc. (IQT). IQT is the non-profit strategic investor that identifies and accelerates the development of innovative technologies to support the mission of the U.S. Intelligence Community.

This strategic partnership and investment allows Kailos to continue the development of NGS laboratory and software solutions that may benefit the intelligence community. "Kailos Genetics' combination of genomic technologies represents an approach that is unique in the marketplace," said Tom Gillespie, Investment Partner at IQT, "We believe that further development of this technology will provide valuable capabilities for both the public and private sector."

"We're excited to partner with IQT to continue our development of solutions for the identification of genetic materials," said Troy Moore, chief scientific officer of Kailos Genetics. "This partnership will foster positive outcomes for the intelligence community."

To learn more about Kailos Genetics, visit www.kailossolutions.com.

‍About Kailos

‍Kailos Genetics is an innovator in next-generation sequencing technologies, with best-in-class target enrichment chemistries combined with proprietary analysis and reporting software for a complete solution. TargetRich‚Ñ¢ provides a simple work flow with robust performance for superior analytic results for next-generation sequencing assays. Kailos Blue is a proprietary, modular laboratory information system with modules for managing samples in the laboratory environment, analytics, and full reporting. Founded in 2010, and based in Huntsville's HudsonAlpha Institute for Biotechnology, Kailos is committed to providing a simple, trusted and affordable solution to laboratories looking to launch next-generation sequencing solutions. To learn more, visit www.kailossolutions.com.

No items found.